|
Off-Label Settlements |
|||
|
2004 |
Pfizer |
$430M |
Neurontin (Gabapentin) |
|
2007 |
Bristol-Myers Squibb |
$515M |
Abilify (aripiprazole) |
|
2009 |
Pfizer |
$2.3B |
Godeon (ziprasidone) |
|
2009 |
Eli Lilly |
$1.415BB |
Zyprexa (olanzapine) |
|
2010 |
AstraZeneca |
$520M |
Seroquel (quetiapine) |
|
2012 |
Abbott Labs |
$1.5B |
Depakote (divalproex sodium) |
|
2012 |
GlaxoSmithKline |
$3B |
Paxil (paroxetine) |
|
2013 |
Johnson & Johnson |
$2.2B |
Risperdal (risperidone) |